Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors
Thrombosis Research · 2023
DOI: 10.1016/j.thromres.2023.06.021 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Thrombosis Research, 2023. Verfasst von Gregory Pon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Memorial Hermann - Texas Medical Center, 6411 Fannin St, Houston, TX 77030, United States of America. Hauptthemen laut MEDLINE: Hemostatics, Blood Coagulation Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: 4-F PCC is administered for reversal of factor Xa inhibitor-associated coagulopathy despite a lack of quality evidence demonstrating hemostatic efficacy. The aim of this study was to evaluate the hemostatic efficacy of 4-F PCC in intracerebral hemorrhage patients who received factor Xa inhibitors versus warfarin. MATERIALS AND METHODS: This was a multi-center, retrospective, observational cohort study at a large healthcare system. Patients taking warfarin received 4-F PCC 25-50 units/kg based on the presenting INR, while patients taking a factor Xa inhibitor received 35 units/kg. The primary outcome was the percentage of patients with good or excellent hemostatic efficacy as assessed by modified Sarode scale, with neurologic outcomes assessed as a secondary endpoint. Patients were included in the primary outcome population if they had a repeat CT scan within 24 h. RESULTS: One hundred fifty-seven patients were included in the primary outcome population; [warfarin (n = 76), factor Xa inhibitors (n = 81)]. Hemostatic efficacy was 83 % in the warfarin group versus 75 % in the factor Xa inhibitor group (p = 0.24). The hemostatic efficacy risk difference between the groups was 7.6 % (95 % CI 5.1 %, 20.2 %). Good neurologic outcome (mRS 0-2) at discharge was 17 % in warfarin patients versus 12 % in the factor Xa inhibitor patients (p = 0.40). CONCLUSIONS: There was no significant difference in hemostatic efficacy or clinical outcomes between patients taking warfarin or a factor Xa inhibitor following reversal with 4-F PCC. This study provides further support that 4-F PCC can be used for the reversal of factor Xa inhibitor-associated coagulopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Memorial Hermann - Texas Medical Center, 6411 Fannin St, Houston, TX 77030, United States of America.
- Department of Neurology, McGovern Medical School at The University of Texas Health Science Center of Houston, 6431 Fannin St, Houston, TX 77030, United States of America; Mercy Hospital, Fort Smith, AR 72913, United Sta…
- Department of Neurology, McGovern Medical School at The University of Texas Health Science Center of Houston, 6431 Fannin St, Houston, TX 77030, United States of America; Division of Neurology, Baptist Memorial Hospital…
- Center for Clinical and Translational Sciences, McGovern Medical School at The University of Texas Health Science Center of Houston, 7000 Fannin St, Houston, TX 77030, United States of America; Department of Internal Me…
- Department of Neurology, McGovern Medical School at The University of Texas Health Science Center of Houston, 6431 Fannin St, Houston, TX 77030, United States of America.
- Department of Hematology, McGovern Medical School at The University of Texas Health, Science Center of Houston, 6410 Fannin St, STE 830, Houston, TX 77030, United States of America.
Zitieren
APA
Pon, G., Pelsue, B., Reddy, S. T., Parsha, K., Zhang, X., Gulbis, B., Barreto, A., Savitz, S. I., Escobar, M., & Allison, T. A. (2023). Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors. Thrombosis Research. https://doi.org/10.1016/j.thromres.2023.06.021
Vancouver
Pon G, Pelsue B, Reddy ST, Parsha K, Zhang X, Gulbis B, et al. Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors. Thrombosis Research. 2023. doi:10.1016/j.thromres.2023.06.021
BibTeX
@article{Pon2023,
author = {Pon, Gregory and Pelsue, Brittany and Reddy, Sujan Teegala and Parsha, Kaushik and Zhang, Xu and Gulbis, Brian and Barreto, Andrew and Savitz, Sean I and Escobar, Miguel and Allison, Teresa A},
title = {Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors},
journal = {Thrombosis Research},
year = {2023},
doi = {10.1016/j.thromres.2023.06.021}
}
EUVIMED